Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 22, 2021Health PolicyOpen Access

Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey

View Full Paper
Ask AI
Bookmark
Share

Authors

PRPierluigi RussoAgostino Gemelli University PolyclinicACAngelica CarlettoItalian Medicines AgencyGNGergely Németh

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Russo et al. (2021) studied this question.

synapsesocial.com/papers/6a8369e30c529eac175f4016https://doi.org/10.1016/j.healthpol.2021.06.008
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference2021 · 13 citations
  2. 2Pricing and reimbursement of orphan drugs: the need for more transparency2011 · 263 citations
  3. 3Incentives and disincentives to drug innovation: evidence from recent literature2019 · 21 citations
  4. 4Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia2017 · 117 citations